Senechio Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-06-2024
- Paid Up Capital ₹ 0.10 M
as on 16-06-2024
- Company Age 13 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 7.50 M
as on 16-06-2024
- Revenue 13.44%
(FY 2022)
- Profit 15.28%
(FY 2022)
- Ebitda -33.88%
(FY 2022)
- Net Worth 30.10%
(FY 2022)
- Total Assets -16.80%
(FY 2022)
About Senechio Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.50 M.
Bhanu Chaudhary and Sachin Verma serve as directors at the Company.
- CIN/LLPIN
U51397DL2011PTC220092
- Company No.
220092
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 May 2011
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Senechio Pharma Private Limited offer?
Senechio Pharma Private Limited offers a wide range of products and services, including Hair Care, Hair Growth Supplements, Skin Care, Sunscreen Products, Health Conditions, Mental Wellness, Heart Care, Protein Supplements, Amino Acids, Facewash.
Who are the key members and board of directors at Senechio Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhanu Chaudhary  | Director | 01-Nov-2018 | Current |
| Sachin Verma | Director | 31-May-2011 | Current |
Financial Performance of Senechio Pharma.
Senechio Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 13.44% increase. The company also saw a substantial improvement in profitability, with a 15.28% increase in profit. The company's net worth Soared by an impressive increase of 30.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Senechio Pharma?
In 2021, Senechio Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 30 Dec 2022 | ₹7.50 M | Open |
How Many Employees Work at Senechio Pharma?
Senechio Pharma has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Senechio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Senechio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
